Lord Abbett & CO. LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 23.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,096,784 shares of the biopharmaceutical company’s stock after selling 2,413,534 shares during the period. Pfizer makes up approximately 0.8% of Lord Abbett & CO. LLC’s investment portfolio, making the stock its 6th biggest position. Lord Abbett & CO. LLC owned 0.14% of Pfizer worth $271,971,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in PFE. K.J. Harrison & Partners Inc raised its position in Pfizer by 11.9% during the first quarter. K.J. Harrison & Partners Inc now owns 48,639 shares of the biopharmaceutical company’s stock valued at $1,664,000 after purchasing an additional 5,159 shares in the last quarter. Callahan Advisors LLC raised its position in Pfizer by 1.9% during the first quarter. Callahan Advisors LLC now owns 279,334 shares of the biopharmaceutical company’s stock valued at $9,556,000 after purchasing an additional 5,176 shares in the last quarter. Beaumont Financial Partners LLC raised its position in Pfizer by 17.1% during the first quarter. Beaumont Financial Partners LLC now owns 8,597 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 1,254 shares in the last quarter. Grandfield & Dodd LLC raised its position in Pfizer by 0.3% during the first quarter. Grandfield & Dodd LLC now owns 83,230 shares of the biopharmaceutical company’s stock valued at $2,847,000 after purchasing an additional 250 shares in the last quarter. Finally, Usca Ria LLC raised its position in Pfizer by 19.6% during the first quarter. Usca Ria LLC now owns 331,931 shares of the biopharmaceutical company’s stock valued at $11,355,000 after purchasing an additional 54,492 shares in the last quarter. Institutional investors and hedge funds own 69.89% of the company’s stock.

Shares of Pfizer Inc. (PFE) opened at $37.20 on Friday. The firm has a market capitalization of $217,387.00, a price-to-earnings ratio of 14.59, a P/E/G ratio of 2.57 and a beta of 1.01. Pfizer Inc. has a 1-year low of $30.90 and a 1-year high of $37.22. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business posted $0.61 earnings per share. equities analysts anticipate that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were issued a $0.32 dividend. The ex-dividend date was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.44%. Pfizer’s payout ratio is 79.01%.

Several brokerages have commented on PFE. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. J P Morgan Chase & Co set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, November 1st. Jefferies Group set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Thursday, November 16th. Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, October 31st. Finally, Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $38.77.

In other Pfizer news, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total transaction of $262,027.50. Following the sale, the executive vice president now owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.

WARNING: “Pfizer Inc. (PFE) Shares Sold by Lord Abbett & CO. LLC” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/16/pfizer-inc-pfe-shares-sold-by-lord-abbett-co-llc.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related stocks with our FREE daily email newsletter.